Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Views - The company reported a total revenue of 954 million yuan in Q1 2025, reflecting a year-on-year increase of 0.28%. The total profit amounted to 64.86 million yuan, down 6.44% year-on-year. The net profit attributable to the parent company was 68.64 million yuan, up 8.9% year-on-year, while the net profit excluding non-recurring items was 65.06 million yuan, showing a slight increase of 0.21% year-on-year [2][4]. Summary by Sections Financial Performance - In Q1 2025, the company achieved total revenue of 9.54 billion yuan, with a total profit of 648.6 million yuan and a net profit attributable to the parent company of 686.4 million yuan [2][4]. - The gross profit margin increased by 2.47 percentage points year-on-year to 33.09%, while the net profit margin rose by 0.57 percentage points to 7.19% [10]. Business Outlook - Domestic business pressures are gradually easing, with the company actively exploring new retail channels and membership-based supermarkets to mitigate the impact of structural adjustments in the health product industry [10]. - The company is also expanding its global footprint, with local factories in Germany and the United States, which are expected to reduce the impact of tariff changes on its overseas business [10]. Profit Forecast - The company forecasts net profits of 370 million yuan, 438 million yuan, and 491 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 1.56, 1.84, and 2.07 yuan [10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][10] Core Views - The company's revenue for 2024 reached 4.211 billion yuan, a year-on-year increase of 17.56%, with a net profit attributable to shareholders of 0.325 billion yuan, up 15.66% year-on-year [6] - In Q1 2025, the company achieved revenue of 0.954 billion yuan, a slight increase of 0.28% year-on-year, and a net profit of 0.069 billion yuan, up 8.90% year-on-year [6] - The company is positioned as a leading CDMO in the health food industry, with a focus on product innovation and technological upgrades, supported by a global supply capability across China, the US, and Europe [9] Summary by Sections Recent Performance - The company's performance in the last year shows a mixed trend, with a 1-month decline of 4.7% and a 12-month decline of 9.5% compared to the CSI 300 index [4] - As of April 25, 2025, the current stock price is 25.41 yuan, with a market capitalization of approximately 6.029 billion yuan [4] Regional Performance - In 2024, revenue by region was as follows: China 1.661 billion yuan (down 10.28%), Europe 0.604 billion yuan (up 14.25%), Americas 1.666 billion yuan (up 59.56%), and other regions 0.280 billion yuan (up 77.38%) [6] - The Chinese market showed signs of recovery in Q1 2025, with revenue stabilizing due to the company's efforts in expanding new consumer markets [6] Product Performance - In 2024, revenue by product type was: soft capsules 1.984 billion yuan (up 29.91%), tablets 0.326 billion yuan (down 10.05%), powders 0.232 billion yuan (down 20.90%), gummies 0.995 billion yuan (up 34.54%), beverages 0.248 billion yuan (down 41.22%), hard capsules 0.223 billion yuan (up 46.83%), and other forms 0.177 billion yuan (up 141.32%) [6] - The company has seen significant growth in high-margin products like gummies, which have increased their market share from approximately 5% in 2022 to nearly 10% in 2024 [6] Profitability - The gross margin for 2024 was 31.46%, improving to 33.09% in Q1 2025, reflecting a year-on-year increase of 1.19 percentage points and 2.47 percentage points respectively [6] - The company’s net profit margin for 2024 was 7.72%, slightly decreasing to 7.19% in Q1 2025 [7] Financial Forecast - The projected revenue for 2025 is 4.663 billion yuan, with a net profit of 0.400 billion yuan, and EPS of 1.69 yuan [8] - The company expects a revenue growth rate of 11% in 2025, with a net profit growth rate of 23% [8] Competitive Position - The company is enhancing its competitive barriers through multi-dimensional capability improvements, including product innovation, supply chain optimization, and digital transformation [9] - The company’s innovative products contributed over 35% to sales in 2024, with higher gross margins than average [9]

Group 1: Company Performance - In Q1 2025, the company achieved a net profit of 68.64 million RMB, representing an 8.90% year-on-year increase [6] - The gross profit margin for Q1 2025 was 33.09%, an increase of 2.47 percentage points compared to the same period last year [6] - For the full year 2024, the company reported total revenue of 4.21 billion RMB, a 17.6% increase year-on-year, and a net profit of 325 million RMB, up 15.7% [8] Group 2: Market and Growth Strategy - The Chinese nutrition and health food market is projected to reach 260.2 billion RMB in 2024, with a CAGR of 6.3% from 2019 to 2024 [8] - The company plans to enhance its global smart supply chain capabilities and strengthen collaboration between domestic and international operations [2][7] - The company aims to expand its domestic market share by focusing on high-value clients and exploring new consumption channels such as live streaming and offline retail [2][7] Group 3: International Business and Challenges - Approximately 60% of the company's business is international, with 40% coming from the U.S. market [3] - The company is actively managing the impact of tariffs on its U.S. exports, with less than 15% of its total revenue coming from exports to the U.S. [3] - The company is exploring local production options in the U.S. to mitigate tariff impacts and enhance its supply chain resilience [3] Group 4: Product Development and Innovation - The company focuses on six key functional areas: anti-aging, probiotics, beauty and health, cardiovascular metabolism, immune enhancement, and bone and joint health [5] - The company is developing a "Xianle Probiotic Technology Platform" to lead the probiotics industry and is responding to national initiatives on weight management with new product launches [5] - The production capacity utilization rate for gummies and bagged drinks exceeded 70% as of March 2025, while powder products still have room for improvement [4]

2025Q1 毛利率同增2pct 至33.09%，主要系采购端降本叠加优化定价策略所致，销售/管理费用率分别同 增2pct/2pct 至9.33%/11.85%，主要系销售团队升级及市场营销推广所致，净利率同增0.3pct 至5.92%， 基本持平。 事件 2025 年4 月23 日，仙乐健康发布2025 年一季度报告。 2025Q1 总营收9.54 亿元（同增0.3%），高基数下增速边际放缓，归母净利润0.69 亿元（同增9%），扣 非净利润0.65亿元（同增0.2%）。 投资要点 降本增效持续推进，盈利能力保持稳定 内生外延释放规模，海外市场加速开拓 公司一方面通过产品创新与运营优化提升内生业务，另一方面BF 贡献外延式增长。分地区来看，国内 通过重组销售团队，建立新零售赛道BD 团队，推动内外部资源共享与整合，有望助推国内业务企稳回 升；美洲BF 规模效应持续显现，目前在手订单充足；欧洲自动化包装生产线投产缩短本地交付周期， 后续公司持续优化产品清单，提升现有品牌和渠道客户体量。 盈利预测 我们短期看好公司通过推动一系列整合措施和降本增效措施，促进BF 盈利能力提升，长期看好公司产 品研发创新能力、B ...

Investment Rating - The report maintains a "Buy" investment rating for the company [7] Core Views - The company's Q1 2025 total revenue reached 954 million yuan, reflecting a year-on-year growth of 0.3%, while the net profit attributable to shareholders was 69 million yuan, up 9% year-on-year [4][5] - The company is focusing on cost reduction and efficiency improvement, with a gross margin increase of 2 percentage points to 33.09% due to cost savings in procurement and optimized pricing strategies [5] - The company is expanding its overseas market presence while enhancing its domestic operations through product innovation and operational optimization [6] Summary by Sections Financial Performance - Q1 2025 revenue was 954 million yuan, with a year-on-year growth of 0.3% - Net profit attributable to shareholders was 69 million yuan, up 9% year-on-year - Non-recurring net profit was 65 million yuan, reflecting a 0.2% increase year-on-year [4] Cost Management - Gross margin improved by 2 percentage points to 33.09% - Selling and administrative expense ratios increased by 2 percentage points each to 9.33% and 11.85%, respectively, due to sales team upgrades and marketing promotions [5] Growth Strategy - The company is leveraging both organic growth through product innovation and external growth via business expansion - Domestic operations are being stabilized through the restructuring of sales teams and the establishment of new retail channels - The Americas market is showing scale effects with sufficient orders, while the European automated packaging production line has been launched to shorten local delivery times [6] Earnings Forecast - The company is expected to achieve EPS of 1.73, 2.23, and 2.70 yuan for 2025, 2026, and 2027, respectively, with corresponding PE ratios of 15, 11, and 10 times [7][10]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Views - The company reported a total revenue of 4.211 billion yuan for 2024, representing a year-on-year increase of 17.56%. The net profit attributable to the parent company was 325 million yuan, up 15.66% year-on-year, while the net profit excluding non-recurring items was 328 million yuan, reflecting a 16.7% increase [2][4] - In Q4 2024, the company achieved a total revenue of 1.163 billion yuan, which is a 7.74% year-on-year increase. However, the net profit attributable to the parent company decreased by 11.09% to 85.26 million yuan, and the net profit excluding non-recurring items fell by 5.14% to 91.38 million yuan [2][4] Summary by Sections Financial Performance - The company's revenue for 2024 was 4.211 billion yuan, with a gross profit margin of 31.46%, an increase of 1.2 percentage points year-on-year. The net profit margin was 7.72%, down 0.13 percentage points from the previous year [10] - The revenue breakdown shows that domestic revenue was 1.661 billion yuan, down 10.28% year-on-year, while revenue from the Americas was 1.666 billion yuan, up 59.56% year-on-year. European revenue reached 604 million yuan, a 14.25% increase [10] Business Strategy - The company is actively exploring new retail channels and membership-based supermarkets in China to mitigate pressure on domestic sales. The establishment of local factories in Germany and the United States is expected to reduce the impact of tariff changes [10] - The company anticipates that its net profit will reach 370 million yuan in 2025, 438 million yuan in 2026, and 491 million yuan in 2027, with corresponding EPS of 1.56, 1.84, and 2.07 yuan, respectively [10]

Investment Rating - The report maintains a "Strong Buy" rating for the company [2] Core Views - The company has successfully navigated challenges in 2024 and is expected to see improvements in 2025, with a focus on adjusting customer structures to adapt to channel shifts. The backdrop of boosting domestic demand is anticipated to lead to gradual revenue recovery in China [5][6] - Despite tariff disruptions in the Americas, the company is actively negotiating cost transfers with clients and dynamically assessing the feasibility of capacity transfers. Strategic partnerships in other regions are being deepened to expand market coverage [5][6] - The company aims to be a leader in the global nutrition and health food industry, with proactive overseas market and global supply chain layouts revealing diverse growth potential [5] Financial Performance Summary - In 2024, the company achieved revenue of 4.21 billion and net profit of 325 million, representing year-on-year growth of 17.6% and 15.7% respectively. The fourth quarter of 2024 saw revenues of 1.16 billion, with a net profit of 90 million, showing a year-on-year increase of 7.7% [5][6] - For the first quarter of 2025, the company reported revenues of 954 million, with net profit of 69 million, reflecting a slight year-on-year increase of 0.3% in revenue and 8.9% in net profit [5][6] - The company’s revenue from different regions in 2024 showed a decline in China by 10.3%, while the Americas saw a significant increase of 59.6% [5][6] - The gross margin improved to 31.5% in 2024 and 33.1% in Q1 2025, driven by cost reduction strategies and pricing optimization [5][6] Growth Projections - The company forecasts total revenue growth from 3.58 billion in 2023 to 4.84 billion in 2025, with a compound annual growth rate (CAGR) of 15% [6][14] - Earnings per share (EPS) are projected to increase from 1.18 in 2023 to 1.62 in 2025, indicating a positive growth trajectory [6][14] - The report anticipates continued improvement in profitability, with net profit margins expected to stabilize around 7.9% by 2025 [6][14]

证券研究报告·公司点评报告·食品加工 仙乐健康（300791） 2025 年一季报点评：积极调整，稳扎稳打 2025 年 04 月 24 日 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 3,582 | 4,211 | 4,701 | 5,346 | 5,984 | | 同比（%） | 42.87 | 17.56 | 11.64 | 13.71 | 11.95 | | 归母净利润（百万元） | 281.04 | 325.06 | 391.89 | 496.65 | 585.57 | | 同比（%） | 32.39 | 15.66 | 20.56 | 26.73 | 17.90 | | EPS-最新摊薄（元/股） | 1.18 | 1.37 | 1.65 | 2.09 | 2.47 | | P/E（现价&最新摊薄） | 20.75 | 17.94 | 14.88 | 11.74 | 9.96 | 证券分析师 苏铖 ...

Core Viewpoint - Xianle Health reported a positive performance in Q1 2025, with revenue growth and improved profit margins, indicating strong market positioning and growth potential in both domestic and international markets [1][2][3] Group 1: Financial Performance - In Q1 2025, the company achieved revenue of 954 million yuan, a year-on-year increase of 0.28% [1] - The net profit attributable to shareholders reached 68.64 million yuan, reflecting a year-on-year growth of 8.90% [1] - The gross profit margin was 33.09%, an increase of 2.47 percentage points compared to the previous year [1] Group 2: Domestic Business Development - The company maintained positive revenue growth in the China region despite a high base from the previous year, with order growth outpacing revenue growth [1] - Xianle Health expanded its leading position in the domestic market by targeting new consumer markets and enhancing its MCN channel [1] - The company successfully launched 13 major products and established a global product map, creating vertical solutions [1] Group 3: International Business Strategy - The company adopted a localized operational strategy to enhance its global business layout, responding quickly to market demands [2] - In the Americas, despite tariff-related uncertainties, the company reported a strong start with improved gross margins and significant order growth [2] - The European business performed well, establishing partnerships with top brands in Southern Europe, while the Asia-Pacific region saw a gross margin exceeding 45%, the highest since 2022 [2] Group 4: Research and Innovation - Xianle Health emphasized research and development by establishing an Anti-Aging Research Institute and launching innovative products [2] - New products include QUICKFIZZ probiotic drinks and DHA algae oil gummies, which received regulatory approval [2]

盈利预测与投资评级：当前中国区表现已呈现改善迹象，有望在新消费市场实现重点突破，美洲区BF 核心业务扭亏进入攻坚期，人效提升显著，期待逐步改善。我们预计公司2025-27 年可实现归母净利润 4.00/5.00/5.68 亿元，同比分别+23.01%/+24.94%/+13.75%，当前股价对应2025-27 年PE 分别为 15X/12X/11X，维持"推荐"评级。 25Q1 收入保持平稳，中国区趋势良好，欧洲区大客户实现突破。25Q1 公司收入端实现平稳增长，其 中：1）中国区：实现收入正增长，订单增速高于收入增速，趋势良好；2）美洲区：美洲出口业务实现 稳健开局，且出口业务毛利率同比提升，BF 新增订单增速显著，BF 核心业务的扭亏进入攻坚期；3） 欧洲区：收入同比增长超35%，订单总量增长超30%，公司与南欧头部品牌达成战略合作，并对其拉美 公司产生积极的溢出效应；4）亚太及新兴地区：深化澳洲战略客户合作，同步扩大印尼、泰国等东南 亚市场覆盖，新品销售收入突破百万级，营养软糖品类收入增长超20%。 毛利率有效提升，盈利能力保持稳定。25Q1 公司毛利率/归母净利率分别为33.09%/7.19%，同比 ...